NCT00038194View on ClinicalTrials.gov

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Prostate Cancer
Interventions
DRUG

imatinib mesylate

DRUG

docetaxel

Trial Locations (1)

77030

U.T. M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER